SCOR Global Life Embedded Value increases 29% to EUR 4.5 billion in 2013 (EUR 24.10 per share), continuing to provide the Group with significant earnings and strong capital repatriation
SCOR Global P&C’s April renewals.
The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets
The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets
The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets.
The pharmaceutical industry has been actively seeking the ideal treatment for hepatitis C for years: a treatment whose features would be an eradication of the virus from the body in 100% of cases.
The pharmaceutical industry has been actively seeking the ideal treatment for hepatitis C for years: a treatment whose features would be an eradication of the virus from the body in 100% of cases.
The Deepwater Horizon accident has led to a re-evaluation of deepwater drilling procedures.
Availability of the documents relating to the 2014 combined general shareholders' meeting.
